Medical Device Procurement in Japan: A Supplier's Guide [2026]

Japan is the world's second-largest single-country medical device market after the United States, valued at approximately JPY 3.5 trillion (USD 25 billion). With an aging population driving healthcare demand, universal health insurance coverage, and sophisticated hospitals, Japan represents a premium market for medical device suppliers. However, the regulatory pathway is uniquely complex, and procurement customs differ significantly from Western markets.

Regulatory authority and approval pathway

The Pharmaceuticals and Medical Devices Agency (PMDA) regulates medical devices under the Pharmaceutical and Medical Device Act (PMD Act), overseen by the Ministry of Health, Labour and Welfare (MHLW).

• Shonin (approval): Class III and IV devices require Shonin — a full pre-market approval involving clinical data review, quality system audit, and PMDA consultation. Timelines range from 12 to 24 months.
• Ninsho (certification): Class II devices with established Japanese standards can use the faster Ninsho pathway through Registered Certification Bodies (RCBs). Timelines are typically 6-10 months.
• Todokede (notification): Class I devices require only notification to PMDA.
• Marketing Authorization Holder (MAH): Foreign manufacturers must appoint a Japanese MAH (Designated Marketing Authorization Holder — D-MAH) who holds legal responsibility for the device in Japan.
• QMS compliance: Japan's QMS Ministerial Ordinance (MHLW Ordinance No. 169) aligns with ISO 13485 but includes Japan-specific requirements. QMS audits are conducted by PMDA or RCBs.

Japan does not automatically recognize FDA clearance or CE marking. However, PMDA participates in the IMDRF and accepts international clinical data if studies include Japanese patient populations or justification for extrapolation.

Key procurement platforms and channels

• National and prefectural hospital tenders: Japan's national hospitals (under the National Hospital Organization) and prefectural/municipal hospitals publish tenders through government procurement portals. The Japan External Trade Organization (JETRO) provides English-language guidance.
• JPAL (Japan Payer Assessment List): Medical devices must be listed on the national reimbursement price list to be purchased by hospitals covered under the universal health insurance system. MHLW sets reimbursement prices through the C1/C2 application process for new technologies.
• Group Purchasing Organizations: Large hospital groups like NTT Medical Center, JCHO, and university hospital networks aggregate purchasing.
• Distributor networks: Japan's distribution ecosystem is highly intermediated. Major distributors (Medipal, Alfresa, Suzuken in pharma; specialized device distributors regionally) play a critical role in hospital access.

Compliance requirements for tenders

• Japanese-language documentation: All regulatory submissions, labeling, IFU, and tender responses must be in Japanese.
• JIS standards: Certain device categories must comply with Japanese Industrial Standards in addition to international standards.
• Post-market surveillance: Japan requires rigorous post-market surveillance including use-results surveys and re-examination within specified periods.
• Reimbursement alignment: Tender responses must reference the MHLW reimbursement code and price. Pricing above reimbursement levels makes hospital purchase economically unviable.

Market size and opportunity

Japan's rapidly aging population (29% over 65) creates sustained demand across device categories:

• Orthopedic implants: Joint replacement and spinal devices driven by elderly patient volumes.
• Cardiovascular devices: Stents, pacemakers, and structural heart devices.
• Endoscopy: Japan leads globally in endoscopic technology adoption and innovation.
• Robotics and AI diagnostics: Government programs (Society 5.0) actively promote healthcare technology adoption.

Tips for foreign suppliers

1. Choose your MAH partner carefully: Your D-MAH controls your regulatory fate in Japan. Select a partner with strong PMDA relationships and category expertise.
2. Plan for long timelines: From Shonin application to first hospital sale, expect 18-30 months. Start early and maintain consistent PMDA engagement.
3. Secure reimbursement listing: Without JPAL listing at an economically viable price, hospital procurement is effectively blocked. Engage MHLW reimbursement discussions early.
4. Build clinical evidence with Japanese sites: PMDA strongly prefers clinical data from Japanese populations. Conduct bridging studies or include Japanese sites in global trials.
5. Leverage tender automation for scale: Japan's fragmented hospital market requires responding to high volumes of individual tenders. MedStrato's platform helps manage this complexity. Book a demo to learn more.